Investigating how platinum chemotherapy affects immune responses in small cell lung cancer
Platinum-induced lipid reprogramming and tumor immune microenvironment in SCLC
This study is looking at how a common chemotherapy treatment affects the immune system in patients with small cell lung cancer, with the goal of finding better ways to help the body fight the cancer using immune therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10868735 on NIH RePORTER |
What this research studies
This research focuses on small cell lung cancer (SCLC), a highly aggressive form of lung cancer with a very low survival rate. It aims to understand how platinum-based chemotherapy influences the immune environment of tumors and the effectiveness of immune checkpoint inhibitors, which are treatments designed to enhance the body's immune response against cancer. The study will explore the role of dendritic cells, which are crucial for initiating immune responses, and how they may become dysfunctional in the presence of tumor-derived substances. By examining these interactions, the research seeks to uncover mechanisms that could improve treatment outcomes for patients with SCLC.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with small cell lung cancer who are undergoing or considering treatment with platinum-based chemotherapy.
Not a fit: Patients with other types of lung cancer or those who are not receiving platinum-based chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for small cell lung cancer, potentially enhancing patient survival rates.
How similar studies have performed: Previous research has shown promising results in understanding immune responses in cancer treatment, but this specific approach to SCLC is relatively novel.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Jin, Lingtao — University of Texas Hlth Science Center
- Study coordinator: Jin, Lingtao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.